Business interruption caused by natural disasters and infectious diseases, and BCPs
First written in FY2017. 6 of 14 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2026: 11 of 88 companies on the "Worse" side.
- FY2025AdvancedAnnual report
「BCP/BCM: Conducted initial-response drills for large-scale disasters in January 2025. Began discussions on BCM coordination with the IT Solutions Headquarters and the Production Headquarters (production group companies).」
As a response to the risk of business interruption caused by natural disasters and infectious diseases, conducted initial-response drills for large-scale disasters and began discussions on BCM coordination with the IT and production divisions. - FY2024MitigatedAnnual report
「Assuming major earthquakes such as an earthquake directly beneath the Tokyo metropolitan area, we are reviewing and updating the BCPs of our core business divisions and implementing measures to ensure business continuity.」
As a response to the risk of business interruption caused by natural disasters and infectious diseases, reviewed and updated the BCPs of core business divisions and conducted drills and other measures. - FY2023MitigatedAnnual report
「To reduce these risks, we are working across the supply chain to reduce greenhouse gas emissions, including through energy-saving activities, the use of renewable energy and greater efficiency in development and production processes, as well as formulating a BCP (business continuity plan) across the Group.」
Organized the response to the risk of business interruption caused by natural disasters and infectious diseases as supply-chain-wide measures including greenhouse-gas reductions, renewable energy, energy conservation and BCPs. - FY2023-Q3RestatedAnnual report
「The risk associated with COVID-19 may fluctuate due to a resurgence or other factors, but we will continue to formulate measures from a medium- to long-term perspective by constantly monitoring the latest information and carefully organizing the risks and opportunities.」
Continued to monitor information, organize risks and opportunities, and formulate measures from a medium- to long-term perspective, assuming the risk of a resurgence of infectious diseases. - FY2022-Q3MitigatedAnnual report
「During the cumulative third quarter of the fiscal year (1 April 2021 to 31 December 2021), supply issues caused by semiconductor shortages and other factors became apparent in the Imaging business, and the digital camera market was unable to secure sufficient supply. In the Precision Equipment business, capital investment in FPD-related fields remained firm for both large panels and small- and medium-sized panels. Capital investment in semiconductor-related fields was also on an expansionary trend. In the Healthcare business, market conditions generally remained strong in the Life Science Solutions and Eye Care Solutions fields.」
While the impact of business interruptions and market weakness caused by infectious diseases remained, capital investment in the Precision Equipment business expanded and market conditions in the Healthcare business were strong. However, supply constraints caused by semiconductor shortages became apparent in the Imaging business. - FY2022-Q2MitigatedAnnual report
「During the cumulative second quarter of the fiscal year, economic conditions were affected by the prolonged impact of COVID-19. However, supported by the wider adoption of vaccinations and fiscal stimulus in various countries, the economy continued to recover, led by the United States and China, and was generally on a recovery trend from the downturn caused by the COVID-19 crisis.」
Disclosed that although the impact of business interruptions and market weakness caused by infectious diseases remained, the economy and individual businesses were recovering against a backdrop of vaccinations and fiscal stimulus. - FY2022-Q1MitigatedAnnual report
「In the Healthcare business, although the impact of COVID-19 remained in all regions in the Life Science Solutions and Eye Care Solutions fields, an overall recovery trend continued.」
Although the impact of business interruptions and market weakness caused by infectious diseases remained, the Healthcare business generally continued to recover across regions. - FY2021RestatedAnnual report
「The risk associated with the spread of COVID-19 may continue to fluctuate significantly due to further spread or a resurgence, but we will continue to formulate measures from a medium- to long-term perspective by constantly monitoring the latest information and carefully organizing the risks and opportunities.」
Continued to address the risk of business interruption caused by the further spread or resurgence of infectious diseases by monitoring information, organizing risks and opportunities, and formulating measures from a medium- to long-term perspective. - FY2021-Q3RestatedAnnual report
「The risk associated with the spread of COVID-19 may continue to fluctuate significantly due to further spread or a resurgence, but we will continue to formulate measures from a medium- to long-term perspective by constantly monitoring the latest information and carefully organizing the risks and opportunities.」
Continued to address the risk of business interruption caused by the further spread or resurgence of infectious diseases by monitoring the latest information, organizing risks and opportunities, and formulating measures. - FY2021-Q2RestatedAnnual report
「In the Healthcare business, market conditions remained sluggish in both the Bioscience and Ophthalmic Diagnostic fields, which were significantly affected by the spread of COVID-19.」
Disclosed that market weakness caused by the spread of infectious diseases continued to affect the Healthcare business. - FY2021-Q1RestatedAnnual report
「In the Healthcare business, sales of products deferred from the fourth quarter of the previous fiscal year progressed to some extent in both the Bioscience and Ophthalmic Diagnostic fields, although business activities, including sales activities, were constrained.」
Although business interruptions and constraints on sales activities caused by infectious diseases continued during the quarter, sales of products deferred from the previous fiscal year progressed to some extent. - FY2020MaterialisedAnnual report
「The spread of COVID-19 caused a decline in demand in the Imaging business, delays in component supplies and situations in which installation work for FPD exposure equipment in the Precision Equipment business could not be carried out as planned, affecting the Group's consolidated results for the fiscal year.」
Previously identified risks relating to infectious diseases and business interruption materialized as a decline in demand, delays in component supplies and installation delays caused by COVID-19. - FY2018RestatedAnnual report
「We are paying close attention to measures against natural disasters, including major earthquakes, fires, floods and droughts, including those caused by abnormal weather and climate change, as well as the spread of infectious diseases such as novel influenza, and have formulated a BCP (business continuity plan). However, if catastrophic damage occurs at the Group's development and manufacturing sites or suppliers, operations may be suspended and production or shipments may be delayed.」
Continued to disclose the risk of business interruption caused by natural disasters or infectious diseases and the response through BCPs. - FY2017First statedAnnual report
「We are paying close attention to measures against natural disasters, including floods and droughts caused by major earthquakes, fires and abnormal weather, as well as the spread of infectious diseases such as novel influenza, and have formulated a BCP (business continuity plan). However, if catastrophic damage occurs at the Group's development and manufacturing sites or suppliers, operations may be suspended and production or shipments may be delayed.」
Added the risk of interruptions to development, manufacturing and procurement caused by natural disasters or infectious diseases, and the response through BCP formulation, as a new risk item.